动物胃食道逆流症市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球动物胃食道逆流症市场价值为 31 亿美元，预计到 2034 年将以 7.5% 的复合年增长率增长，达到 63 亿美元，这得益于伴侣动物和牲畜中 GERD 患病率的不断上升，以及兽医诊断和治疗技术的进步。人口老化、肥胖和胃肠道感染等因素导致动物患有 GERD，对有效治疗方案的需求增加。该市场的特点是拥有各种诊断工具和治疗干预措施，包括抗酸剂、H2 拮抗剂和质子帮浦抑制剂，这些药物在兽医学中广泛用于控制 GERD 症状。这些药物有助于减少胃酸，并且由于其在动物身上的安全性和有效性得到证实而成为常用处方药。

此外，兽医诊断技术的进步，例如内视镜成像、先进的血液检测和超音波技术，使兽医能够更早、更准确地检测胃食道逆流症 (GERD)。这促进了早期介入策略的推广，从而显着改善治疗效果并减少长期併发症。宠物主人对消化系统疾病对宠物整体健康影响的认识不断提高，也加速了对非处方药和处方药的需求。

2024年，动物胃食道逆流症（GERD）市场的治疗领域产值达17亿美元。抗酸剂、H2拮抗剂和质子帮浦抑制剂等药物已被证明能够持续有效地降低动物胃酸水平，这对于控制GERD症状至关重要。这些药物广泛用于人用和兽用製剂，由于其安全性和极低的副作用，多年来一直被用于兽药。

2024年，伴侣动物细分市场占最大份额，达71.7%。宠物肥胖率不断上升，导致许多伴侣动物营养不良。饮食问题常常导致胃酸逆流，增加了对胃食道逆流（GERD）治疗方案的需求。某些犬种，例如哈巴狗、斗牛犬和拳师犬，由于其独特的解剖特征，特别容易患上GERD。

由于宠物饲养数量的增加以及兽医服务需求的不断增长，美国动物胃食道逆流症市场在2024年的价值达到12亿美元。宠物主人和牲畜饲养者越来越意识到胃肠道健康的重要性及其对动物整体福祉的影响。政府在疾病预防和动物福利方面的措施进一步支持了市场的成长。

全球动物胃食道逆流症市场的主要参与者包括勃林格殷格翰、硕腾、默克、礼来、希尔思宠物营养、爱德士实验室、嘉里集团、Vetcare、Vetoquinol 和维克。这些公司积极参与开发并提供一系列诊断和治疗解决方案，以应对动物胃食道逆流症 (GERD)。他们的努力旨在改善受影响动物的生活质量，并满足兽医行业对有效治疗日益增长的需求。为了巩固市场地位，动物胃食道逆流症 (GERD) 市场的公司正在采取各种策略。他们专注于研发，以推出创新的诊断工具和治疗方案。他们正在与兽医诊所和研究机构合作，以增强产品供应并扩大市场覆盖范围。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 动物胃肠道疾病盛行率不断上升
    • 动物健康意识不断提高
    • 诊断工具的技术进步
    • 增加宠物拥有量和宠物人性化
  • 产业陷阱与挑战
    • 监管挑战和可靠性问题
    • 内视镜和pH监测程序成本高昂
• 成长潜力分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供应方影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按产品，2021 - 2034 年

• 主要趋势
• 诊断
  • 测试类型
    • 实验室检查
    • 兽医影像
    • 其他诊断测试
  • 最终用途
    • 兽医医院和诊所
    • 兽医诊断中心
    • 其他最终用途
• 治疗
  • 药品类别
    • 抗酸药
    • H2受体阻断剂
    • 质子帮浦抑制剂（PPI）
    • 促动力剂
    • 其他药物类别
  • 给药途径
    • 口服
    • 注射剂

第六章：市场估计与预测：依动物类型，2021 - 2034 年

• 主要趋势
• 伴侣动物
• 牲畜

第七章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第八章：公司简介

• Boehringer Ingelheim
• Daiichi Sankyo
• Elanco Animal Health
• Hill's Pet Nutrition
• IDEXX Laboratories
• Kerry Group
• Merck
• Vetcare
• Vetoquinol
• Vibrac
• Zoetis

The Global Animal Gastroesophageal Reflux Disease Market was valued at USD 3.1 billion in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 6.3 billion by 2034, driven by the increasing prevalence of GERD among both companion and livestock animals, as well as advancements in veterinary diagnostics and treatments. Factors such as aging populations, obesity, and gastrointestinal infections contribute to the development of GERD in animals, leading to a higher demand for effective treatment options. The market is characterized by the availability of various diagnostic tools and therapeutic interventions, including antacids, H2 antagonists, and proton pump inhibitors, which are widely used in veterinary medicine to manage GERD symptoms. These medications help reduce stomach acid and are commonly prescribed due to their proven safety and efficacy profiles in animals.

In addition, advancements in veterinary diagnostics, such as endoscopic imaging, advanced blood panels, and ultrasound technologies, are making it easier for veterinarians to detect GERD earlier and with greater precision. This has led to an uptick in early intervention strategies, which can significantly improve outcomes and reduce long-term complications. The increasing awareness among pet owners about the impact of digestive disorders on overall pet health is also accelerating demand for both over-the-counter and prescription solutions.

The treatment segment in the animal gastroesophageal reflux disease market generated USD 1.7 billion in 2024. Medications such as antacids, H2 antagonists, and proton pump inhibitors have shown consistent effectiveness in reducing stomach acid in animals, which is crucial for controlling GERD symptoms. These medications are widely available in both human and veterinary formulations and have been used in veterinary medicine for years due to their safety and minimal side effects.

The companion animals segment held the largest share of 71.7% in 2024. Obesity in pets is on the rise, leading to nutritional deficits in many companion animals. Dietary issues often lead to the development of acid reflux, increasing the need for GERD treatment options. Certain dog breeds, such as pugs, bulldogs, and boxers, are particularly susceptible to GERD due to their unique anatomical features.

United States Animal Gastroesophageal Reflux Disease Market was valued at USD 1.2 billion in 2024, owing to the increasing number of pet ownership and the growing demand for veterinary services. There is a rising awareness among pet owners and livestock breeders regarding the importance of gastrointestinal health and its impact on overall animal well-being. Government initiatives focusing on disease prevention and animal welfare further support market growth.

Key players in the Global Animal Gastroesophageal Reflux Disease Market include Boehringer Ingelheim, Zoetis, Merck, Elanco, Hill's Pet Nutrition, IDEXX Laboratories, Kerry Group, Vetcare, Vetoquinol, and Virbac. These companies are actively involved in developing and offering a range of diagnostic and therapeutic solutions to address GERD in animals. Their efforts aim to improve the quality of life for affected animals and meet the growing demand for effective treatments in the veterinary sector. To strengthen their market position, companies in the animal GERD market are adopting various strategies. They are focusing on research and development to introduce innovative diagnostic tools and treatment options. Collaborations with veterinary clinics and research institutions are being pursued to enhance product offerings and expand market reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal diseases in animals
    • 3.2.1.2 Rising awareness of animal health
    • 3.2.1.3 Technological advancements in diagnostic tools
    • 3.2.1.4 Increased pet ownership and pet humanization
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Regulatory challenges and reliability concerns
    • 3.2.2.2 High cost of endoscopic and pH monitoring procedures
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Diagnostics
  • 5.2.1 Test type
    • 5.2.1.1 Laboratory tests
    • 5.2.1.2 Veterinary imaging
    • 5.2.1.3 Other diagnostic tests
  • 5.2.2 End use
    • 5.2.2.1 Veterinary hospital and clinics
    • 5.2.2.2 Veterinary diagnostic centers
    • 5.2.2.3 Other end use
• 5.3 Treatment
  • 5.3.1 Drug class
    • 5.3.1.1 Antacids
    • 5.3.1.2 H2 receptor blockers
    • 5.3.1.3 Proton pump inhibitors (PPIs)
    • 5.3.1.4 Pro-kinetic agents
    • 5.3.1.5 Other drug classes
  • 5.3.2 Route of administration
    • 5.3.2.1 Oral
    • 5.3.2.2 Injectables

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
• 6.3 Livestock animals

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE

Chapter 8 Company Profiles

• 8.1 Boehringer Ingelheim
• 8.2 Daiichi Sankyo
• 8.3 Elanco Animal Health
• 8.4 Hill's Pet Nutrition
• 8.5 IDEXX Laboratories
• 8.6 Kerry Group
• 8.7 Merck
• 8.8 Vetcare
• 8.9 Vetoquinol
• 8.10 Vibrac
• 8.11 Zoetis